Professional
Added to YB: 2024-08-22
Pitch date: 2024-06-30
EXAS [bullish]
Exact Sciences Corporation
+144.71%
current return
Author Info
No bio for this author
Company Info
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally.
Market Cap
$19.7B
Pitch Price
$42.21
Price Target
85.00 (-18%)
Dividend
N/A
EV/EBITDA
187.48
P/E
-93.68
EV/Sales
6.55
Sector
Biotechnology
Category
growth
Baron Discovery Fund New Position: Exact Sciences Corporation
EXAS: Leader in CRC screening w/ Cologuard ($2B rev). 92% CRC sensitivity vs blood tests' 50%. $7.5B greenfield opportunity. Cologuard Plus launch 2025, 30% fewer false positives. Oncotype DX dominates breast cancer recurrence testing. Trading at 3x 2025 EV/Sales. Risks: FDA approval of Guardant's blood test, increased marketing spend.
Read full article (4 min)